文献速递消化、代谢与肾脏急症

Nazartinib(EGF816)在EGFR突变非小细胞肺癌成人患者中的安全性和疗效:一项多中心、开放标签、1期研究

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.
PubMed 文献 · Lancet Respir Med · 2020-01-15
一句话结论在晚期EGFR突变NSCLC患者中,Nazartinib 150mg每日一次片剂被确定为2期推荐剂量,安全性良好,皮肤毒性以低级别斑丘疹为主且极少需减量。

这项多中心、开放标签1期剂量递增研究纳入180例晚期EGFR突变NSCLC患者,口服Nazartinib(75-350mg,每日一次,连续28天方案),采用贝叶斯逻辑回归模型指导剂量递增。虽未达到最大耐受剂量,但确定150mg每日一次片剂为2期推荐剂量;6例(3%)患者出现7例次剂量限制性毒性。最常见不良事件为皮疹(62%,多为1-2级)、腹泻(45%)、瘙痒(39%)、乏力(30%)和口腔炎(30%);任何原因3-4级不良事件发生于99例(55%),最常见为皮疹(15%)、肺炎(7%)、贫血(6%)和呼吸困难(5%);疑似药物相关严重不良事件16例(9%)。作者认为Nazartinib安全性良好,皮肤毒性以低级别斑丘疹为主,所需减量极少。

要点

  • 在180例晚期EGFR突变NSCLC患者中,Nazartinib的2期推荐剂量确定为150mg每日一次(片剂),虽未达到最大耐受剂量。
  • 剂量限制性毒性共7例次,发生于6例(3%)接受150mg、225mg或350mg每日一次的患者中。
  • 任何原因3-4级不良事件发生于99例(55%)患者,最常见为皮疹(15%)、肺炎(7%)、贫血(6%)和呼吸困难(5%)。
  • 疑似药物相关严重不良事件发生于16例(9%)患者。
  • 最常见不良事件为皮疹(62%,其中斑丘疹40%、痤疮样皮炎12%)、腹泻(45%)、瘙痒(39%)、乏力(30%)和口腔炎(30%),多为1-2级。

适用人群与场景

  • 年龄≥18岁、组织学或细胞学确诊的IIIB-IV期EGFR突变非小细胞肺癌患者,允许不同EGFR突变状态和既往治疗史。
  • 至少有一个可测量病灶,东部肿瘤协作组(ECOG)体能状态评分≤2。

处置流程与药物剂量

  • Nazartinib以胶囊或片剂形式口服,每日一次,连续28天为一个给药周期。
  • 剂量递增采用两参数贝叶斯逻辑回归模型,遵循过量控制递增原则,在75mg至350mg之间共7个剂量水平进行。
  • 2期推荐剂量为150mg每日一次(片剂)。

研究设计与关键结果

  • 研究类型:多中心、开放标签、1/2期研究中的1期剂量递增部分,在位于欧洲、亚洲和北美的九家学术医疗中心开展。
  • 样本量:180例患者接受Nazartinib治疗,其中女性116例(64%),中位年龄60岁(52-69岁),ECOG体能状态1分者116例(64%)。
  • 剂量分布:75mg组17例、100mg组38例、150mg组73例、200mg组8例、225mg组28例、300mg组5例、350mg组11例。
  • 主要终点:未达到最大耐受剂量,2期推荐剂量确定为150mg每日一次(片剂);6例(3%)患者出现7例次剂量限制性毒性,发生于接受150mg、225mg或350mg每日一次的患者中。
  • 关键不良事件:任何原因最常见不良事件为皮疹(所有亚类共111例[62%],其中斑丘疹72例[40%]、痤疮样皮炎22例[12%])、腹泻81例(45%)、瘙痒70例(39%)、乏力54例(30%)、口腔炎54例(30%),多为1-2级。
  • 任何原因3-4级不良事件发生于99例(55%)患者,最常见为皮疹(所有亚类合并27例[15%])、肺炎12例(7%)、贫血10例(6%)、呼吸困难9例(5%)。
  • 疑似药物相关严重不良事件发生于16例(9%)患者。

证据类型、等级与局限

  • 证据类型:1期剂量递增研究(开放标签、多中心)。
  • 作者结论:Nazartinib安全性良好,皮肤毒性以低级别斑丘疹为主,所需减量极少。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在晚期EGFR突变NSCLC患者中,Nazartinib 150mg每日一次(片剂)被确定为2期推荐剂量,虽未达到最大耐受剂量。
  • Nazartinib的皮肤毒性以低级别斑丘疹为主,所需减量极少(作者结论)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Resistance to first-generation and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is mediated by the emergence of the Thr790Met mutation in 50-60% of treated patients with non-small-cell lung cancer (NSCLC). We aimed to assess the safety and activity of nazartinib (EGF816), a third-generation EGFR TKI that selectively inhibits EGFR with Thr790Met or activating mutations (or both), while sparing wild-type EGFR, in patients with advanced EGFR-mutant NSCLC.

METHODS: This phase 1 dose-escalation part of an open-label, multicentre, phase 1/2 study was conducted at nine academic medical centres located in Europe, Asia, and North America. Patients were included if they were aged 18 years or older and had stage IIIB-IV EGFR-mutant NSCLC (with varying statuses of EGFR mutation and previous therapy allowed), at least one measurable lesion, and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. Nazartinib (at seven dose levels between 75 mg and 350 mg, in capsule or tablet form) was administered orally, once daily, on a continuous 28-day dosing schedule. A two-parameter Bayesian logistic regression model, guided by the escalation with overdose control principle, was implemented to make dose recommendations and estimate the maximum tolerated dose or recommended phase 2 dose of nazartinib (the primary outcome). This study is registered with ClinicalTrials.gov (NCT02108964); enrolment to phase 1 is complete and the study is ongoing.

FINDINGS: By Aug 31, 2017, 180 patients (116 [64%] women; median age 60 years (52-69); 116 [64%] with ECOG performance status 1) received nazartinib across seven dose levels: 75 mg (n=17), 100 mg (n=38), 150 mg (n=73), 200 mg (n=8), 225 mg (n=28), 300 mg (n=5), and 350 mg (n=11). Seven dose-limiting toxicities were observed in six (3%) patients who received 150 mg, 225 mg, or 350 mg nazartinib once daily. Although the maximum tolerated dose was not met, the recommended phase 2 dose was declared as 150 mg once daily (tablet). The most common adverse events, regardless of cause, were rash (all subcategories 111 [62%] patients, maculopapular rash 72 [40%], dermatitis acneiform 22 [12%]), diarrhoea (81 [45%]), pruritus (70 [39%]), fatigue (54 [30%]), and stomatitis (54 [30%]), and were mostly grades 1-2. Any-cause grade 3-4 adverse events were reported in 99 (55%) patients across all doses, the most common being rash (all subcategories grouped 27 [15%]), pneumonia (12 [7%]), anaemia (ten [6%]), and dyspnoea (nine [5%]). Serious adverse events suspected to be drug-related occurred in 16 (9%) patients.

INTERPRETATION: Nazartinib has a favourable safety profile, with low-grade skin toxicity characterised by a predominantly maculopapular rash that required minimal dose reductions.

FUNDING: Novartis Pharmaceuticals Corporation.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Tan DS, Leighl NB, Riely GJ, et al. Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. Lancet Respir Med. 2020. PMID: 31954624. doi:10.1016/S2213-2600(19)30267-X

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。